EUVIMEDEUVIMED entdecken
Crossref

QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment

Anupama Sikder, Shraddha Naresh Katarpawar, Rahul Kumar, Vivek Phatale, Ganesh Vambhurkar, Giriraj Pandey, Suraj Wagh, Abhishek Sharma, Etikala Amulya, Pooja Khairnar, Amol G Dikundwar, Saurabh Srivastava

European Journal of Pharmaceutics and Biopharmaceutics · 2026-08 · 225 · 115121

DOI: 10.1016/j.ejpb.2026.115121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-08. Verfasst von Anupama Sikder und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Res…. Hauptthemen laut MEDLINE: Piperidines, Adenine, Glioblastoma, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Institute of Pharmaceutical Education and Research, Ahmedabad.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ibrutinib (IBR), a potent Bruton's tyrosine kinase (BTK) inhibitor, has demonstrated promising anticancer potential; however, its poor solubility, limited bioavailability and restricted permeability across the blood-brain barrier (BBB) significantly constrain its therapeutic application in glioblastoma (GBM). For GBM therapy, overcoming the formidable BBB remains a major obstacle. In the current research, a pH-sensitive liposomal formulation encapsulating IBR (IBR-LIPO) was developed to facilitate direct nose-to-brain (N2B) delivery and enhance brain targeting. The optimized IBR-LIPO depicted a spherical morphology with a mean particle size below 200 nm, as confirmed by transmission electron microscopy (TEM) and dynamic light scattering (DLS). The optimized formulation depicted a zeta potential of -31.8 ± 0.95 indicating good stability. The formulation depicted an entrapment efficiency and drug loading of 85.46 ± 1.35% and 4.5 ± 0.34% respectively. The incorporation of cholesteryl hemisuccinate (CHS) conferred pH-responsive behavior, resulting in controlled yet initial-burst release profile in acidic conditions. Ex vivo nasal permeation and toxicity studies revealed a 2.54-fold enhancement in the nasal permeation with no signs of toxicity. In vitro evaluation using 2D and 3D cell culture revealed significantly improved cytotoxicity of IBR-LIPO compared to the free drug. In vivo pharmacokinetic analysis depicted enhanced brain delivery with a 2.30-fold enhancement in drug targeting efficiency (%DTE) and a 2.39-fold increase in direct transport percentage (%DTP) and a higher drug targeting index (DTI) over free IBR following intranasal (IN) administration. Collectively, these findings highlight IBR-LIPO as a promising nanocarrier for efficient N2B delivery and targeted GBM therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesAdenineGlioblastomaBrainBrain NeoplasmsAntineoplastic AgentsLiposomesAnimalsHydrogen-Ion ConcentrationAdministration, IntranasalHumansBlood-Brain BarrierCell Line, TumorTissue DistributionParticle SizeMaleRats

Stichwörter der Autor:innen

3D spheroidsGlioblastomaIbrutinibQuality by designpH sensitive liposomes

Substanzen

LiposomesPiperidinesibrutinibAdenineAntineoplastic Agents

Autor:innen und Institutionen

  • Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
  • Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India. Electronic address: saurabh@niperhyd.…

Förderung

  • National Institute of Pharmaceutical Education and Research, Ahmedabad

Zitieren

APA

Sikder, A., Naresh Katarpawar, S., Kumar, R., Phatale, V., Vambhurkar, G., Pandey, G., Wagh, S., Sharma, A., Amulya, E., Khairnar, P., Dikundwar, A. G., & Srivastava, S. (2026). QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European Journal of Pharmaceutics and Biopharmaceutics, 225, 115121. https://doi.org/10.1016/j.ejpb.2026.115121

Vancouver

Sikder A, Naresh Katarpawar S, Kumar R, Phatale V, Vambhurkar G, Pandey G, et al. QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European Journal of Pharmaceutics and Biopharmaceutics. 2026;225:115121. doi:10.1016/j.ejpb.2026.115121

BibTeX
@article{Sikder2026,
  author = {Sikder, Anupama and Naresh Katarpawar, Shraddha and Kumar, Rahul and Phatale, Vivek and Vambhurkar, Ganesh and Pandey, Giriraj and Wagh, Suraj and Sharma, Abhishek and Amulya, Etikala and Khairnar, Pooja and Dikundwar, Amol G and Srivastava, Saurabh},
  title = {QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  volume = {225},
  pages = {115121},
  doi = {10.1016/j.ejpb.2026.115121}
}
Kostenlos starten →